Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Propionyl-CoA carboxylase beta chain (PCCB) is one of two essential subunits forming the mitochondrial biotin-dependent enzyme propionyl-CoA carboxylase. This multimeric complex catalyzes the ATP-dependent conversion of propionyl-CoA to D-methylmalonyl-CoA—a critical step in breaking down odd-chain fatty acids and certain amino acids. The alpha subunit provides biotin binding/carboxyation activity while the beta chain contains the catalytic site responsible for transferring CO₂ from biotin to propionyl-CoA. Mutations affecting either PCCA (alpha) or PCCB (beta) genes cause autosomal recessive disorders such as propionic acidemia, characterized by severe neonatal-onset metabolic acidosis if untreated. The only current interventions involve dietary management, cofactor supplementation with biotin when responsive, organ transplantation, or experimental gene therapies[1][2][3][4].
For supportive therapies: - Biotin acts as an essential cofactor required for enzymatic activity. For gene therapy or future approaches: - Gene replacement or editing to restore functional PCCB expression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Propionyl-CoA carboxylase beta chain (PCCB).